Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero , Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday,
View HTML
Toggle Summary Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation.
View HTML
Toggle Summary Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at predefined blinded first
View HTML
Toggle Summary VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides further insight to potential mechanisms of action VASCEPA is the first and only agent studied on top of
View HTML
Toggle Summary Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today
View HTML
Toggle Summary Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates,
View HTML
Toggle Summary Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades Veteran Cardiovascular Commercial Executive Hired to Lead Focused Launch DUBLIN, Ireland and BRIDGEWATER, N.J., Aug.
View HTML
Toggle Summary Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
Total Revenue Increased 34% in Second Quarter 2020 Compared to Second Quarter 2019  Despite COVID-19 Headwinds Multiple Upcoming Milestones Regarding VASCEPA ® Opportunity in United States and Internationally Management to Host Conference Call Today at 7:30 a.m.
View HTML
Toggle Summary VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention
VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA
View HTML
Toggle Summary Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2020 financial results and provide an operational update
View HTML

Amarin Corporation